Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC
Invited conference paper presented and published in conference proceedings


Times Cited
Web of Science8WOS source URL (as at 26/09/2020) Click here for the latest count
Altmetrics Information
.

Other information
All Author(s) ListRudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Hernandez G, Foster P, Spahn J, O'Hear C, Gettinger S
Name of ConferenceIASLC 19th World Conference on Lung Cancer
Start Date of Conference23/09/2018
End Date of Conference26/09/2018
Place of ConferenceToronto
Country/Region of ConferenceCanada
Journal nameJournal of Thoracic Oncology
Proceedings TitleJOURNAL OF THORACIC ONCOLOGY
Title of PublicationJOURNAL OF THORACIC ONCOLOGY
Year2018
Month10
Volume Number13
Issue NumberSuppl 10
PublisherELSEVIER SCIENCE INC
Article numberMA15.02
PagesS407 - S407
ISSN1556-0864
eISSN1556-1380
LanguagesEnglish-United Kingdom
Keywordsatezolizumab, Erlotinib, NSCLC
Web of Science Subject CategoriesOncology;Respiratory System;Oncology;Respiratory System

Last updated on 2020-27-09 at 03:10